Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Leone BA, Vallejo CT, Romero AO, Machiavelli MR, Pérez JE, Leone J, Leone JP (2016) Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat. doi:10.​1007/​s10549-016-4066-7
2.
Skandalakis JE, Skandalakis LJ, Skandalakis PN (2007) Anatomy of the lymphatics. Surg Oncol Clin N Am 16(1):1–16CrossRefPubMed
3.
Karatas F, Sahin S, Erdem GU, Ates O, Babacan T, Akin S, Sever AR, Ozisik Y, Altundag K (2016) Left laterality is an independent prognostic factor for metastasis in N3 stage breast cancer. J BUON 21(4):851–858PubMed
Metadata
Title
The effects of laterality in stage IV breast cancer patients at initial diagnosis; much work is needed!
Author
Kadri Altundag
Publication date
01-02-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4103-1

Other articles of this Issue 3/2017

Breast Cancer Research and Treatment 3/2017 Go to the issue

Epidemiology

Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis

Clinical trial

Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?

Clinical trial

Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

Clinical trial

Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

Epidemiology

Recurrence risk perception and quality of life following treatment of breast cancer

Clinical trial

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits